Science and Research
AVONELLE-X: A Multicenter, Open-Label Extension Study to Evaluate the Longterm Safety and Tolerability of Faricimab in Patients with Neovascular Age-Related Macular Degeneration
This study evaluates the long-term safety and tolerability of faricimab in participants with neovascular age-related macular degeneration (AMD).
Overview
This is a multicenter long-term extension study designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intravitreal injection at a personalized treatment interval to participants with neovascular age-related macular degeneration who enrolled in and completed one of the Phase III studies: GR40306 (NCT03823287) or GR40844 (NCT03823300), also referred to as the parent studies.
Eligible patients who consent to participate in this study will be enrolled upon completion of the end-of-study visit in the parent study.
- Principal Investigator
Dr Sukhpal Sandhu
This is a multicenter long-term extension study designed to evaluate the long-term safety and tolerability of faricimab 6 milligrams (mg) administered by intravitreal injection at a personalized treatment interval to participants with neovascular age-related macular degeneration who enrolled in and completed one of the Phase III studies: GR40306 (NCT03823287) or GR40844 (NCT03823300), also referred to as the parent studies.
Eligible patients who consent to participate in this study will be enrolled upon completion of the end-of-study visit in the parent study.
- Principal Investigator
Learn more
View this study on ClinicalTrials.gov
See the ClinicalTrials.gov database listing for more detailed information about this study.